Zacks small cap research.

Zacks Investment Research has three different main subscription plans: Zacks Premium, Zacks Investor Collection, and Zacks Ultimate. Zacks Premium costs …

Zacks small cap research. Things To Know About Zacks small cap research.

By Ann Heffron, CFA, CPA OTC:CPKF READ THE FULL CPKF RESEARCH REPORT Chesapeake Financial’s (OTC:CPKF) third quarter net earnings increased $0.5 million, or 13%, year over year to $4.2 million, while 2022’s third quarter diluted EPS rose by $0.12, or 15%, to $0.90 from $0.78 posted a year ago. Results exclude a one-time gain …Nov 20, 2023 · Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. 1. Reviva RECOVER Topline Results Data Presentation, October 30, 2023. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Earnings Update. • Cash and cash equivalents were $1.5 million at the end of 3Q, down from $3.8 million at the end of 1Q. o During 3Q, Ensysce (NASDAQ:ENSC) completed a convertible note financing offer that netted the company roughly $560,000 before fees and offering expenses, with the potential for another $1.13 million upon “satisfaction ...

Zacks Premium Research for ZSCCX View All Zacks Mutual Fund Rank #1's View the Zacks Mutual Fund Rank Guide Annual Return * 1 = Top 20%, 5 = Bottom 20% …

By Thomas Kerr, CFA. NASDAQ:GRIL. READ THE FULL GRIL RESEARCH REPORT. Muscle Maker Inc. (NASDAQ:GRIL), has evolved into a diversified, global food company with two distinct business units: 1) Sadot LLC – an international agricultural commodity supply-chain organization and 2) MMI Restaurant Group – an operator and franchisor of 50+ healthier-for-you fast casual concepts plus a subscription ...MIRA Continues to Pursue New Pain Relief. 11/14/2023. By Brad Sorensen, CFA. NASDAQ:MIRA. READ THE FULL MIRA RESEARCH REPORT. MIRA (NASDAQ:MIRA) reported 3Q earnings of -$0.26 per share as it...

The small-cap index Russell 2000 recently witnessed its most impressive week in over two years as investors bet on the Federal Reserve's halt in its interest rate …Zacks Rank N/A Third Quarter Update Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 November 15, 2021 312-265-9588 / [email protected] Revenue Q1 Q2 Q3 Q4 Year (Mar) (Jun) (Sep) (Dec) (Dec)In today’s digital age, having a reliable and fast internet connection is essential. When searching for an internet provider, you may come across terms like “unlimited data” and “data caps.” Understanding these terms is crucial to ensure yo...Zacks Small Cap Research coverage specifically looks to focus on small and micro-cap companies that are under followed or under valued by Wall Street. Our analysts seek to identify and report...

By David Bautz, PhD NASDAQ:TNXP READ THE FULL TNXP RESEARCH REPORT Business Update In-House Research Capabilities Bolstered Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has increased its in-house research capabilities with the purchase, construction, and planned construction of multiple research centers. These facilities will allow the company to have better control over the early

Zacks Small Cap Research coverage specifically looks to focus on small and micro-cap companies that are under followed or under valued by Wall Street. Our analysts seek to identify and report...

INX (OTC:INXDF) announced that Republic Group, described as “a global financial firm operating a digital merchant bank and a network of investment platforms,” is investing $5.25 million into the company in exchange for approximately 9.5% of outstanding shares. The deal, according to INX, values INX at approximately $50 million before the ...A new baseball hat tends to be stiff and uncomfortable, and many people prefer the look of an worn-in hat. Fortunately, fading and distressing a baseball cap is quite easy to do. To prepare for the fading process, wet the bill of the hat.Apr 7, 2022 · YY. 40.15. +4.02%. A complete archive of Small-cap articles from Zacks Investment Research. Our Research, Your Success. By M. Marin NASDAQ:NVX | OTC:NVNXF READ THE FULL NVX RESEARCH REPORT Company positioning to benefit from ramping growth in target verticals Novonix (NASDAQ:NVX) (OTC:NVNXF) has a positive sector tailwind, in our opinion, as it advances its strategy to develop a U.S.-based lithium-ion battery materials …Update on Phase 1 Trial of EPI-7386. ESSA Pharma Inc. (NASDAQ:EPIX) is currently conducting a Phase 1 clinical trial of EPI-7386 in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed on two or more systemic therapies, including at least one second generation anti-androgen therapy ( NCT04421222 ).

Aug 24, 2023 · By Lisa Thompson OTC:NEXCF CSE:TGGL READ THE FULL NEXCF RESEARCH REPORT Nextech (OTC:NEXCF) reported Q2 revenues of $1.4 million, up $100,000 sequentially from Q1 and 153% from Q2 2022. The company had preannounced this number on August 1st. Investors are still awaiting news that Nextech’s 3D modeling services will be available to merchants in Amazon’s Seller Central which is expected to boost Image: Bigstock 5 Top-Ranked Small-Cap Stocks to Boost Your Portfolio in 2021 (revised) Nalak Das December 14, 2020 TITN HZO STRT Better trading starts …Institutional Distribution. A 15-20 page, fully entitled research report, produced within 3-4 weeks that targets the institutional investor, currently distributed to First-Call, Capital IQ, Bloomberg, FactSet, and our own ZRS Platform. Together, these platforms target over 20,000 institutional investors and 90% of all asset and hedge fund managers.Zacks Small-Cap Research Lisa Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 July 22, 2021 PKKFF: Peak Fintech Expects to Grow 145% this Year and Be Profitable Compared to its peers in the fintech space who trade at an average of 12.3 timesSUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

Aug 19, 2022 · Reviva’s Phase III trial designated RECOVER is now underway, a four-week efficacy study followed by a one-year safety extension. The trial will target enrollment of 400 subjects, which as of July 2022 was 20% achieved and continuing to progress slightly ahead of schedule. Based on the construction of the study, which could be extended due to ...

Steven Ralston, CFA, is a Senior Analyst and Director of Research with Zacks Small-Cap Research, with over 30 years of experience in the securities and investment industry. He has covered companies within the Basic/Precious Materials, Industrials, Energy, Biotechnology, Real Estate, Cannabis, Packaged Foods, Consumer and Financial …Q4 2022 gross margin increased to 30.9% from 24.3% a year ago and 29.2% in Q3 2022. The increase was primarily from the elimination of $20 million of low-margin revenues from the closure of the Japanese fab which were replaced by higher-margin sales generated from outside customers. Gross margin dollars increased by $25 million, or 25%.A conference call with investors and analysts was held immediately following the release. 2Q:23 revenues of $3.6 million were ahead of our initial estimates and matched revised company guidance. Net loss per share was ($1.03). Management reiterated its outlook of revenues between $14.0 and $15.0 million in 2023.Zacks Small Cap Research Coverage Universe. For access to our most recent reports, please click on the links below. To join our paid real time email service please enter your email address and select the companies you would like to follow. An email will be sent to you for payment and setup instructions. Special Situations / Steven Ralston, CFA. Apr 18, 2023 · By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT We are initiating coverage of Abeona Therapeutics Inc. (NASDAQ:ABEO) with a valuation of $10.00. Abeona is a biopharmaceutical company developing cell and gene therapies for rare genetic diseases. Its lead clinical program, EB-101, is an autologous cell therapy in development for the treatment of recessive dystrophic epidermolysis On May 9, 2023, Lantern Pharma, Inc. (NASDAQ:LTRN) announced 2022 financial and operational results, filed its Form 10-Q with the SEC and hosted a video webcast to review accomplishments. In the last six weeks, Lantern has dosed its first patient in the Phase II Harmonic study, announced receipt of a patent allowance by the USPTO …

Zacks Small-Cap Research Sponsored – Impartial – Comprehensive October 9, 2023 John D. Vandermosten, CFA 312-265-9588 / [email protected] scr.zacks.com 10 S. …

Alpha-1062 Extended-Release Bioequivalence Study Topline Results. Results from the second bioequivalence study were shared with investors a few weeks ago on August 22, 2022. The data demonstrated pharmacokinetic equivalence between 5 mg of Alpha-1062 delayed release tablets and 8 mg galantamine hydrobromide extended …

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Thomas Kerr, CFA is a Senior Equity Research Analyst with Zacks Small-Cap Research, with over 25 years of securities industry experience in Technology, Consumer, Industrials, Med-Tech, Healthcare & Biotechnology sectors. Prior to joining Zacks in 2021, Tom was Senior Investment Specialist at WestPac Wealth Partners, Chief Investment Officer ... ARDS is a serious lung disorder that results from the small blood vessels of the lung leaking fluid that fills up the alveoli, thus preventing proper oxygen exchange (Stevens et al., 2018). There are many causes of ARDS, including infections (e.g., pneumonia), severe burns, pancreatitis, inhalation of smoke or chemicals, or other serious illnesses.Zacks Equity Research December 04, 2023. Better trading ... Ahead of today’s normal trading session, only the small-cap Russell 2000 is in the green at this …Reviva’s Phase III trial designated RECOVER is now underway, a four-week efficacy study followed by a one-year safety extension. The trial will target enrollment of 400 subjects, which as of July 2022 was 20% achieved and continuing to progress slightly ahead of schedule. Based on the construction of the study, which could be extended due to ...Zacks Small-Cap Research Lisa R. Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 January 18, 2022 Preannounces Q4 Revenues of $8.8 Million up 275% Based on a blended enterprise value to sales multiple of its peers of 5.85 times, we believeBy David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update IGALMI™ Approved by the FDA On April 6, 2022, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced that the U.S ...Aug 1, 2023 · read the full nexcf research report Nextech (OTC:NEXCF) preannounced Q2 revenues of $1.4 million, up $100,000 sequentially from Q1 and 153% from Q2 2022. It expects gross margins to be the same as in Q1 at 38%. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …When it comes to fastening two objects together, cap head bolts and cap head screws are two popular options. They both have a similar appearance, but they differ in their application and usage. In this article, we’ll explore the difference ...Jan 13, 2023 · By Lisa Thompson OTC:NEXCF READ THE FULL NEXCF RESEARCH REPORT Yesterday Nextech (OTC:NEXCF) preannounced preliminary 2022 revenues of $10.3 million for the year or $1.4 million for Q4 2022. While this looks like a miss compared to our model, it includes $958,822 in revenues eliminated from historical product sales booked in Q1 and Q2 due to reclassifying the pet business as a discontinued Nov 22, 2023 · Transitioning to SaaS model from 1-time hardware sales focus, while maintaining traditional business LogicMark, Inc. (NASDAQ:LGMK) is transitioning to a SaaS model from a 1-time hardware sales model, while maintaining its traditional business. LGMK expects new products and services to both diversify ...

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted results from its Ongoing Research of Cytisinicline for Addiction, Vaping (ORCA-V1) trial and hosted a conference call for investors on April 20, 2023. The Phase II ORCA-V1 trial was conducted to measure the safety and effectiveness of 3 mg of cytisinicline dosed three times daily for 12 weeks ...Zacks Rank N/A Correlation Study Complete Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 23, 2022 312-265-9588 / [email protected] Revenue (In millions of USD) Q1 Q2 Q3 Q4 YearInstagram:https://instagram. how to trade cryptoallo.stocklowest intraday margin brokersbarrick gold news © Zacks Small Cap Research - All rights reserved Powered By Q4 Inc. 5.111.2.6 (opens in new window) 5.111.2.6 (opens in new window)GBS: Glucose Biosensor Trial IRB Approval. 04/04/2022. Download (opens in new window) PDF 555 KB best bank stock to buyfanuc corporation The details of 2Q 2023: • Revenue for the quarter came in at $1,480,388, which was more than double the revenue seen in the previous quarter of just over $625,000. • FRX posted a quarterly loss of $0.02 per share, slightly ahead of our estimates due largely to an improvement in the gross margin. • Gross margins improved to a gain of ... real estate syndication platforms Net R&D expenses for the third quarter of 2023 were $3.3 million, compared to $3.8 million during the third quarter of 2022. The decrease was primarily due to decreased costs related to the Phase 3 clinical trial and decreased payroll expense, travel, materials, depreciation, and other activities. G&A expenses for the third quarter of 2023 were ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, ...The following disclosures relate to relationships between Zacks Small-Cap Research ( Zacks SCR ), a division of Zacks Investment Research ( ZIR ), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe. ANALYST DISCLOSURES. Zacks SCR Analysts hereby certify that the view expressed in this research report or article ...